Last Updated: September 29, 2026

Details for New Drug Application (NDA): 216386

✉ Email this page to a colleague

NDA 216386 describes ZAVZPRET, which is a drug marketed by Pfizer and is included in one NDA. It is available from two suppliers. There is one patent protecting this drug. Additional details are available on the ZAVZPRET profile page.

The generic ingredient in ZAVZPRET is zavegepant hydrochloride. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the zavegepant hydrochloride profile page.

Summary for 216386

Tradename:	ZAVZPRET
Applicant:	Pfizer
Ingredient:	zavegepant hydrochloride
Patents:	1

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for 216386

Generic Entry Date for 216386^: ⤷ Start Trial* Constraining patent/regulatory exclusivity: NEW CHEMICAL ENTITY Dosage: SPRAY, METERED;NASAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 216386

Mechanism of Action	Calcitonin Gene-related Peptide Receptor Antagonists

Suppliers and Packaging for NDA: 216386

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
ZAVZPRET	zavegepant hydrochloride	SPRAY, METERED;NASAL	216386	NDA	Pfizer Laboratories Div Pfizer Inc	0069-3500	0069-3500-02	6 BLISTER PACK in 1 CARTON (0069-3500-02) / 1 VIAL, SINGLE-DOSE in 1 BLISTER PACK (0069-3500-01) / .1 mL in 1 VIAL, SINGLE-DOSE
ZAVZPRET	zavegepant hydrochloride	SPRAY, METERED;NASAL	216386	NDA	U.S. Pharmaceuticals	63539-135	63539-135-02	1 BLISTER PACK in 1 CARTON (63539-135-02) / 1 VIAL, SINGLE-DOSE in 1 BLISTER PACK (63539-135-01) / .1 mL in 1 VIAL, SINGLE-DOSE

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	SPRAY, METERED;NASAL			Strength	EQ 10MG BASE/SPRAY
Approval Date:	Mar 9, 2023	TE:		RLD:	Yes
Regulatory Exclusivity Expiration:	Mar 9, 2028
Regulatory Exclusivity Use:	NEW CHEMICAL ENTITY
Patent:	8,481,546	Patent Expiration:	Jun 26, 2034	Product Flag?	Y	Substance Flag?	Y	Delist Request?
Patented Use:	ADMINISTRATION OF ZAVEGEPANT FOR ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA

Expired US Patents for NDA 216386

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	ZAVZPRET	zavegepant hydrochloride	SPRAY, METERED;NASAL	216386-001	Mar 9, 2023	7,220,862	⤷ Start Trial
Pfizer	ZAVZPRET	zavegepant hydrochloride	SPRAY, METERED;NASAL	216386-001	Mar 9, 2023	7,314,883	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.